Spots Global Cancer Trial Database for nk cells
Every month we try and update this database with for nk cells cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma | NCT02280525 | Leukemia | Lenalidomide Rituximab Fludarabine Cyclophosphamid... NK Cells Cytarabine | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| Natural Killer Cell (CYNK-001) Infusions in Adults With AML | NCT04310592 | Leukemia Leukemia, Myelo... Leukemia, Myelo... Neoplasms by Hi... Neoplasms Immunosuppressi... Immunologic Fac... Physiological E... Alkylating Agen... Antimetabolites... Antiviral Agent... Analgesics, Non... Anti-infective ... Analgesics Peripheral Nerv... Hematologic Dis... Hematologic Neo... Leukemia in Rem... Relapsed Adult ... Refractory AML | CYNK-001 | 18 Years - 80 Years | Celularity Incorporated | |
| Reactivating NK Cells in Treating Refractory Head and Neck Cancer | NCT02507154 | Nasopharyngeal ... Head and Neck S... | Cetuximab + NK ... | 21 Years - | National University Hospital, Singapore | |
| Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma | NCT04309084 | Multiple Myelom... Neoplasm, Plasm... Neoplasms by Hi... Neoplasms Hemostatic Diso... Vascular Diseas... Cardiovascular ... Paraproteinemia... Blood Protein D... Hematologic Dis... Hemorrhagic Dis... Lymphoprolifera... Immunoprolifera... Immune System D... Antineoplastic ... Analgesics, Non... Analgesics Sensory System ... Peripheral Nerv... Physiological E... | CYNK-001 | 18 Years - 75 Years | Celularity Incorporated | |
| Safety Study of NK Cells From Sibship to Treat the Recurrence of HCC After Liver Transplantation | NCT02399735 | Hepatocellular ... | Low Dose NK cel... Normal Dose NK ... Normal Dose NK ... | 18 Years - 65 Years | Third Affiliated Hospital, Sun Yat-Sen University | |
| Evaluation of Safety and Efficacy of Allo GDA-201 NK Cells in Patients With Relapsed/Refractory B Cell NHL | NCT05296525 | Non-Hodgkin Lym... | GDA-201 | 18 Years - | Gamida Cell ltd | |
| Clinical Trial of Expanded and Activated Autologous NK Cells to Treat Multiple Myeloma | NCT02481934 | Multiple Myelom... | NKAE cells infu... Lenalidomide Bortezomib | 20 Years - 80 Years | Hospital Universitario 12 de Octubre | |
| NK Cell Infusions With Trastuzumab for Patients With HER2+ Breast and Gastric Cancer | NCT02030561 | Breast Cancer Gastric Cancer | Trastuzumab + N... | 21 Years - 99 Years | National University Hospital, Singapore | |
| NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors | NCT01875601 | Solid Tumors Brain Tumors Sarcoma Pediatric Cance... Neuroblastoma | Recombinant hum... NK Cell Infusio... | 2 Years - 29 Years | National Institutes of Health Clinical Center (CC) | |
| A Phase 1b Study of WU-NK-101 in Combination With Cetuximab | NCT05674526 | Colorectal Canc... Squamous Cell C... | WU-NK-101 - Dos... Cetuximab - Dos... WU-NK-101 - Coh... Cetuximab - Coh... | 18 Years - | Wugen, Inc. | |
| Natural Killer Cells in Acute Leukaemia and Myelodysplastic Syndrome | NCT02123836 | Acute Leukaemia Myelodysplastic... | NK cells | 6 Years - 80 Years | National University Hospital, Singapore | |
| Safety Study of NK Cells From Sibship to Treat the Recurrence of HCC After Liver Transplantation | NCT02399735 | Hepatocellular ... | Low Dose NK cel... Normal Dose NK ... Normal Dose NK ... | 18 Years - 65 Years | Third Affiliated Hospital, Sun Yat-Sen University | |
| Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL | NCT03019666 | Multiple Myelom... Non-Hodgkin Lym... Diffuse Large B... Mantle-Cell Lym... Follicular Lymp... Indolent B Cell... Primary Mediast... Lymphoplasmacyt... | Nicotinamide Ex... | 18 Years - 70 Years | Masonic Cancer Center, University of Minnesota | |
| Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL | NCT03019666 | Multiple Myelom... Non-Hodgkin Lym... Diffuse Large B... Mantle-Cell Lym... Follicular Lymp... Indolent B Cell... Primary Mediast... Lymphoplasmacyt... | Nicotinamide Ex... | 18 Years - 70 Years | Masonic Cancer Center, University of Minnesota | |
| Combination Trastuzumab With Expanded Natural Killer Cells for Treating HER2-positive Gastric Cancer | NCT02805829 | Gastric Cancer | Trastuzumab + N... | 18 Years - 75 Years | Xuzhou Medical University | |
| Natural Killer Cells Function in Patients With Chronic Lymphocytic Leukemia | NCT00934986 | Chronic Lymphoc... | Surface express... | 18 Years - | Institut Paoli-Calmettes | |
| NK Cell Infusions With Trastuzumab for Patients With HER2+ Breast and Gastric Cancer | NCT02030561 | Breast Cancer Gastric Cancer | Trastuzumab + N... | 21 Years - 99 Years | National University Hospital, Singapore | |
| Naltrexone and Propranolol Combined With Immunotherapy | NCT05968690 | Advanced Melano... | Propranolol Naltrexone | 18 Years - | Rutgers, The State University of New Jersey | |
| A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML) | NCT05834244 | Acute Myeloid L... | Azacitidine Venetoclax NK Cells | 18 Years - | M.D. Anderson Cancer Center | |
| Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma | NCT02280525 | Leukemia | Lenalidomide Rituximab Fludarabine Cyclophosphamid... NK Cells Cytarabine | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| Characterization of NK Cells Under First Line Advanced Therapy Either as Curative Therapy for Metastatic Melanoma or as Adjuvant Therapy for High-risk of Recurrence | NCT05062096 | Melanoma | Blood samples Skin biopsy | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Clinical Trial for Autologus NK Cells Alone or in Combination With Isatuximab as Maintenance for Multiple Myeloma | NCT04558931 | Multiple Myelom... | CellProtect Isatuximab | 18 Years - | Karolinska Institutet | |
| Combination of Irreversible Electroporation and NK Immunotherapy for Advanced Pancreatic Cancer | NCT02718859 | Pancreatic Canc... | NK cells irreversible el... | 18 Years - 80 Years | Fuda Cancer Hospital, Guangzhou | |
| Combination of Irreversible Electroporation and NK Immunotherapy for Advanced Pancreatic Cancer | NCT02718859 | Pancreatic Canc... | NK cells irreversible el... | 18 Years - 80 Years | Fuda Cancer Hospital, Guangzhou | |
| A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors | NCT05462873 | Carcinoma, Non-... Carcinoma, Rena... Esophageal Squa... Squamous Cell C... | QEQ278 | 18 Years - | Novartis | |
| Natural Killer Cells in Acute Leukaemia and Myelodysplastic Syndrome | NCT02123836 | Acute Leukaemia Myelodysplastic... | NK cells | 6 Years - 80 Years | National University Hospital, Singapore | |
| Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) | NCT00402558 | Myelodysplastic... Leukemia | Thymoglobulin Busulfan Fludarabine Alloreactive NK... G-CSF Tacrolimus Methotrexate Interleukin-2 | - 70 Years | M.D. Anderson Cancer Center | |
| Randomised Controlled Phase-2 Trial to Determine the Efficacy of Adoptive Immunotherapy With NK Cells in High-risk AML | NCT02229266 | Acute Myeloid L... | NK cells Cytarabine | 60 Years - 99 Years | Technische Universität Dresden | |
| Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma | NCT02650648 | Neuroblastoma High-Risk | cyclophosphamid... NK cells hu3F8 rIL-2 | - | Memorial Sloan Kettering Cancer Center | |
| Cellular Immunity and Renal Cell Cancer | NCT04377113 | NK Cell Mediate... NK Cell Cytokin... Kidney Cancer | 18 Years - | Clinical Hospital Center Rijeka | ||
| INFUSION OF ALLOREACTIVE NATURAL KILLER (NK) CELLS AS CONSOLIDATION STRATEGY FOR ACUTE MYELOID LEUKEMIA PATIENTS | NCT03955848 | Adult Acute Mye... | Alloreactive NK... | - | IRCCS Azienda Ospedaliero-Universitaria di Bologna | |
| Characterisation of T Lymphocytes, NK Cells and Macrophages in Melanoma Patients | NCT01336270 | Melanoma | biological coll... | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM | NCT04489420 | Astrocytoma, Gr... Giant Cell Glio... Glioblastoma Mu... Cyclophosphamid... Immunosuppressi... Immunologic Fac... Physiological E... Molecular Mecha... Antiviral Agent... Anti-infective ... Analgesics, Non... Analgesics Sensory System ... Peripheral Nerv... | CYNK001-IV CYNK001-IT | 18 Years - | Celularity Incorporated | |
| Clinical Trial of Expanded and Activated Autologous NK Cells to Treat Multiple Myeloma | NCT02481934 | Multiple Myelom... | NKAE cells infu... Lenalidomide Bortezomib | 20 Years - 80 Years | Hospital Universitario 12 de Octubre | |
| A Study of Allogenic Natural Killer Cells in Combination With Trastuzumab and Pertuzumab in Adult Patients With Refractory Metastatic Her2 Positive Breast Cancer. NK-ACT-BC_2020 | NCT05385705 | Breast Neoplasm... | Cyclophosphamid... Trastuzumab Pertuzumab NK cells Interleukin-2 | 18 Years - | Vall d'Hebron Institute of Oncology | |
| Natural Killer Cell Immunotherapy in Combination With PARP-inhibition in Acute Myeloid Leukemia | NCT05319249 | Acute Myeloid L... | NK cells Talazoparib 1 M... | 18 Years - | German Cancer Research Center | |
| Natural Killer Cell Immunotherapy in Combination With PARP-inhibition in Acute Myeloid Leukemia | NCT05319249 | Acute Myeloid L... | NK cells Talazoparib 1 M... | 18 Years - | German Cancer Research Center | |
| Characterization of NK Cells Under First Line Advanced Therapy Either as Curative Therapy for Metastatic Melanoma or as Adjuvant Therapy for High-risk of Recurrence | NCT05062096 | Melanoma | Blood samples Skin biopsy | 18 Years - | Assistance Publique - Hôpitaux de Paris | |
| Immunotherapy With NK Cell, Rituximab and Rhu-GMCSF in Non-Myeloablative Allogeneic Stem Cell Transplantation | NCT00383994 | Lymphoma Leukemia Transplantation... Lymphoid Malign... Disorder Relate... | GM-CSF Rituximab NK Cell Infusio... | - | M.D. Anderson Cancer Center | |
| Alloreactive NK Cells for Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) | NCT00402558 | Myelodysplastic... Leukemia | Thymoglobulin Busulfan Fludarabine Alloreactive NK... G-CSF Tacrolimus Methotrexate Interleukin-2 | - 70 Years | M.D. Anderson Cancer Center | |
| Cord Blood Natural Killer (NK) Cells in Leukemia/Lymphoma | NCT02280525 | Leukemia | Lenalidomide Rituximab Fludarabine Cyclophosphamid... NK Cells Cytarabine | 18 Years - 80 Years | M.D. Anderson Cancer Center | |
| Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients | NCT04616209 | Non-small Cell ... | donor-derived N... | 20 Years - 70 Years | Precision Biotech Taiwan Corp. | |
| Measurement of NK Cell Activity in Whole Blood in Subjects Being Screened for Colorectal Cancer Using Colonoscopy | NCT02291198 | Natural Killer ... | NK Vue: NK cell... | 40 Years - | ATGen Canada Inc | |
| Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant | NCT00303667 | Acute Myelogeno... | aldesleukin natural killer ... cyclophosphamid... fludarabine pho... allogeneic hema... total body irra... Thymoglobulin Cyclosporin A cyclophosphamid... fludarabine pho... | 18 Years - 70 Years | Masonic Cancer Center, University of Minnesota | |
| Intraperitoneal Natural Killer Cells and INCB024360 for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer | NCT02118285 | Ovarian Cancer Fallopian Tube ... Primary Periton... | Fludarabine Cyclophosphamid... NK cells IL-2 INCB024360 | 18 Years - | Masonic Cancer Center, University of Minnesota | |
| Effect of NK Cell Immunotherapy on Advanced Lung Adenocarcinoma Adenocarcinoma With EGFR Mutation | NCT03662477 | NK Cell Mediate... | NK cells | 35 Years - 75 Years | Shenzhen Fifth People's Hospital | |
| Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers | NCT05099549 | Squamous Cell C... Carcinoma, Non-... Colorectal Neop... Advanced Solid ... Refractory Tumo... Metastatic Tumo... | AFM24 SNK01 | 18 Years - | NKGen Biotech, Inc. | |
| Study of SUPLEXA in Patients With Metastatic Solid Tumours and Haematologic Malignancies | NCT05237206 | Oncology | SUPLEXA | 18 Years - | Alloplex Biotherapeutics Inc | |
| Adoptive Immunotherapy of High Risk Acute Myeloblastic Leukemia Patients Using Haploidentical Kir Ligand-mismatched Natural Killer Cells | NCT00799799 | Myeloblastic Le... | NK cells | 18 Years - | University of Bologna | |
| Natural Killer Cells Function in Patients With Chronic Lymphocytic Leukemia | NCT00934986 | Chronic Lymphoc... | Surface express... | 18 Years - | Institut Paoli-Calmettes | |
| Clinical Study of Autologous Natural Killer Cells in Multiple Myeloma | NCT04558853 | Multiple Myelom... | autologous NK c... | 18 Years - | Karolinska University Hospital | |
| FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors | NCT04551885 | Solid Tumor, Ad... | FT516 Avelumab Cyclophosphamid... Fludarabine IL-2 | 18 Years - | Fate Therapeutics | |
| A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML) | NCT05834244 | Acute Myeloid L... | Azacitidine Venetoclax NK Cells | 18 Years - | M.D. Anderson Cancer Center | |
| NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors | NCT01875601 | Solid Tumors Brain Tumors Sarcoma Pediatric Cance... Neuroblastoma | Recombinant hum... NK Cell Infusio... | 2 Years - 29 Years | National Institutes of Health Clinical Center (CC) | |
| NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors | NCT01875601 | Solid Tumors Brain Tumors Sarcoma Pediatric Cance... Neuroblastoma | Recombinant hum... NK Cell Infusio... | 2 Years - 29 Years | National Institutes of Health Clinical Center (CC) | |
| Natural Killer Cell (CYNK-001) Infusions in Adults With AML | NCT04310592 | Leukemia Leukemia, Myelo... Leukemia, Myelo... Neoplasms by Hi... Neoplasms Immunosuppressi... Immunologic Fac... Physiological E... Alkylating Agen... Antimetabolites... Antiviral Agent... Analgesics, Non... Anti-infective ... Analgesics Peripheral Nerv... Hematologic Dis... Hematologic Neo... Leukemia in Rem... Relapsed Adult ... Refractory AML | CYNK-001 | 18 Years - 80 Years | Celularity Incorporated | |
| Donor Natural Killer Cells and Aldesleukin in Treating Patients w/High Risk AML Undergoing Donor Stem Cell Transplant | NCT00303667 | Acute Myelogeno... | aldesleukin natural killer ... cyclophosphamid... fludarabine pho... allogeneic hema... total body irra... Thymoglobulin Cyclosporin A cyclophosphamid... fludarabine pho... | 18 Years - 70 Years | Masonic Cancer Center, University of Minnesota | |
| Combination Trastuzumab With Expanded Natural Killer Cells for Treating HER2-positive Gastric Cancer | NCT02805829 | Gastric Cancer | Trastuzumab + N... | 18 Years - 75 Years | Xuzhou Medical University | |
| Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers | NCT05099549 | Squamous Cell C... Carcinoma, Non-... Colorectal Neop... Advanced Solid ... Refractory Tumo... Metastatic Tumo... | AFM24 SNK01 | 18 Years - | NKGen Biotech, Inc. | |
| Naltrexone and Propranolol Combined With Immunotherapy | NCT05968690 | Advanced Melano... | Propranolol Naltrexone | 18 Years - | Rutgers, The State University of New Jersey |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
